Scarica l'app Stockscreener
57.51
1.30%
0.74
Precedente Chiudi:
$56.77
Aprire:
$58.37
Volume 24 ore:
827.83K
Relative Volume:
1.30
Capitalizzazione di mercato:
$1.67B
Reddito:
$232.39M
Utile/perdita netta:
$-26.79M
Rapporto P/E:
-53.23
EPS:
-1.0804
Flusso di cassa netto:
$4.41M
1 W Prestazione:
+6.03%
1M Prestazione:
-2.09%
6M Prestazione:
+21.00%
1 anno Prestazione:
+145.87%
Intervallo 1D:
$55.16
$58.44
Intervallo di 1 settimana:
$54.30
$60.49
Portata 52W:
$17.11
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
57.51 | 1.67B | 232.39M | -26.79M | 4.41M | -1.0804 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
AnaptysBio Ord Shs (ANABV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Eversept Partners LP Takes $5.86 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AnaptysBio Inc (ANAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AnaptysBio Inc (ANAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AnaptysBio, Inc. $ANAB Shares Purchased by 683 Capital Management LLC - MarketBeat
AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AnaptysBio Inc (ANAB) Institutional Confidence - TradingKey
AnaptysBio Inc (ANAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
850-share sale notice by insider at ANAB (NASDAQ: ANAB) via Form 144 - Stock Titan
AnaptysBio (ANAB) director acquires 6,030 shares via RSU vesting - Stock Titan
Director at AnaptysBio (NASDAQ: ANAB) receives 6,030 shares via RSUs - Stock Titan
Director John Orwin of ANAPTYSBIO (NASDAQ: ANAB) settles 6,030 RSUs into common stock - Stock Titan
Granahan Investment Management LLC Reduces Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dennis Mulroy sells multiple ANAB shares (NASDAQ: ANAB) across May–June 2026 - Stock Titan
Sofinnova Investments Inc. Has $13.95 Million Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
Daily Brief United States: SpaceX, Crude Oil, DPC Holdings, CRB Commodity Index, Vistra , AnaptysBio Inc, Kardigan, Aes Corp, GE Vernova , Biomarin Pharmaceutical and more - Smartkarma
ANAB (NASDAQ: ANAB) affiliate files Form 144 to sell 20,000 shares - Stock Titan
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ANAB (NASDAQ: ANAB) affiliate files Form 144 listing multiple share dispositions - Stock Titan
Q2 Earnings Forecast for AnaptysBio Issued By HC Wainwright - MarketBeat
AnaptysBio, Inc. Stock 12‑Month Price Target Raised to $81.5, Implies 50% Upside - TradingView
Morgan Stanley (ANAB) plans 35,000-share sale; multiple insider dispositions listed - Stock Titan
[144] ANAPTYSBIO, INC SEC Filing - Stock Titan
ANAB Assumed by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
H.C. Wainwright initiates AnaptysBio stock coverage with buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates AnaptysBio stock coverage with buy rating - Investing.com
H.C. Wainwright Initiates AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $95 - Moomoo
AnaptysBio Coverage Assumed by HC Wainwright & Co. at Buy - Moomoo
AnaptysBio, Inc. $ANAB Shares Acquired by BNP Paribas Financial Markets - MarketBeat
ANAB (ANAB) insider files Form 144 to sell 20,000 shares via option exercise - Stock Titan
ANAB (NASDAQ: ANAB) Form 144 shows Dennis Mulroy selling multiple lots - Stock Titan
ANAB (NASDAQ: ANAB) director reports multiple stock-option sales, dates listed - Stock Titan
ANAB insider resale filed: 20,000 shares via option (ANAB) - Stock Titan
AnaptysBio earnings up next: First report as royalty company - Investing.com
AnaptysBio (NASDAQ:ANAB) Lowered to "Hold" Rating by Zacks Research - MarketBeat
20,000 ANAB Shares Registered; Dennis Mulroy Sold Multiple Lots (ANAB) - Stock Titan
ANAB (NASDAQ) affiliate to sell 20,000 shares via cash option exercise - Stock Titan
Affiliate of ANAB (NASDAQ: ANAB) to sell 7,691 shares after option exercise - Stock Titan
AnaptysBio posts Form 8937 on tax treatment of First Tracks spin-off dividend - TradingView
Spin-off dividend tax info posted by AnaptysBio (NASDAQ: ANAB) - Stock Titan
ANAB proposes sale of 15,000 shares (NASDAQ: ANAB) - Stock Titan
ANABAnaptysBio Inc Stock Price and Quote - Finviz
AnaptysBio, Inc.Common Stock (NQ: ANAB - FinancialContent
AnaptysBio (ANAB) Slips 2.37% as Stock Approaches Key Support LevelsMoving Average Ribbon - newsline.com
ANAB (NASDAQ: ANAB) director reports May sales and 10,264‑share exercise - Stock Titan
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR) - The Globe and Mail
AnaptysBio (ANAB) may find a bottom soon, here's why you should buy the stock now - MSN
Dennis Mulroy files Form 144 to sell shares (ANAB) - Stock Titan
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating - Moomoo
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):